Alain Li Wan Po

Summary

Country: UK

Publications

  1. doi request reprint When is a genetic test suitable for prime time? Predicting the risk of prostate cancer as a case-example
    A Li-Wan-Po
    National Genetics Education and Development Centre, Morris House, Birmingham Women s Hospital, Birmingham B15 2TG, UK
    Public Health Genomics 13:55-62. 2010
  2. doi request reprint No need for rescue medication (NNR) as an easily interpretable efficacy outcome measure in analgesic trials: validation in an individual-patient meta-analysis of dental pain placebo-controlled trials of naproxen
    A Li-Wan-Po
    Centre for Evidence Based Pharmacotherapy, Nottingham, UK
    J Clin Pharm Ther 38:36-40. 2013
  3. doi request reprint Barking up the wrong genome--we are not alone
    A Li-Wan-Po
    National Genetics Education and Development Centre, c o Birmingham s Women s Hospital, Edgbaston, Birmingham, UK
    J Clin Pharm Ther 36:125-7. 2011
  4. pmc Preventing the aortic complications of Marfan syndrome: a case-example of translational genomic medicine
    Alain Li-Wan-Po
    National Genetics Education and Development Centre, Morris House, c o Birmingham Women s Hospital, Edgbaston, Birmingham, United Kingdom
    Br J Clin Pharmacol 72:6-17. 2011
  5. pmc Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17
    Alain Li-Wan-Po
    National Genetics Education and Development Centre, c o Birmingham Women s Hospital, UK
    Br J Clin Pharmacol 69:222-30. 2010
  6. doi request reprint Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example
    Alain Li-Wan-Po
    National Genetics Education and Development Centre, c o Birmingham Women s Hospital, Edgbaston, UK
    Eur J Clin Pharmacol 66:369-74. 2010
  7. ncbi request reprint Personalised medicine: who is an Asian?
    Alain Li Wan Po
    National Genetics Education and Development Centre, Birmingham, UK
    Lancet 369:1770-1. 2007
  8. pmc Dose-response of minor analgesics in acute pain
    Alain Li Wan Po
    National Genetics Education and Development Centre, Birmingham and Centre for Evidence Based Pharmacotherapy, Nottingham, UK
    Br J Clin Pharmacol 63:268-70. 2007
  9. ncbi request reprint How high should total pain-relief score be to obviate the need for analgesic remedication in acute pain? Estimation using signal detection theory and individual-patient meta-analysis
    A Li Wan Po
    Centre for Evidence Based Pharmacotherapy, Nottingham, UK
    J Clin Pharm Ther 31:161-5. 2006

Collaborators

Detail Information

Publications10

  1. doi request reprint When is a genetic test suitable for prime time? Predicting the risk of prostate cancer as a case-example
    A Li-Wan-Po
    National Genetics Education and Development Centre, Morris House, Birmingham Women s Hospital, Birmingham B15 2TG, UK
    Public Health Genomics 13:55-62. 2010
    ..We hope that this may serve as a case-example for the evaluation of the many new genetic tests being suggested for adoption...
  2. doi request reprint No need for rescue medication (NNR) as an easily interpretable efficacy outcome measure in analgesic trials: validation in an individual-patient meta-analysis of dental pain placebo-controlled trials of naproxen
    A Li-Wan-Po
    Centre for Evidence Based Pharmacotherapy, Nottingham, UK
    J Clin Pharm Ther 38:36-40. 2013
    ..We aimed to assess, through a meta-analysis, whether absence of need for rescue medication (NNR) is a reliable outcome measure in the evaluation of acute pain relief...
  3. doi request reprint Barking up the wrong genome--we are not alone
    A Li-Wan-Po
    National Genetics Education and Development Centre, c o Birmingham s Women s Hospital, Edgbaston, Birmingham, UK
    J Clin Pharm Ther 36:125-7. 2011
    ..Here, we wish to draw attention to how our microbiome may contribute to variability in drug effects...
  4. pmc Preventing the aortic complications of Marfan syndrome: a case-example of translational genomic medicine
    Alain Li-Wan-Po
    National Genetics Education and Development Centre, Morris House, c o Birmingham Women s Hospital, Edgbaston, Birmingham, United Kingdom
    Br J Clin Pharmacol 72:6-17. 2011
    ..If on-going well designed trials confirm their efficacy, the outlook for Marfan syndrome patients would be improved considerably...
  5. pmc Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17
    Alain Li-Wan-Po
    National Genetics Education and Development Centre, c o Birmingham Women s Hospital, UK
    Br J Clin Pharmacol 69:222-30. 2010
    ..Investigators disagree about the phenotype to be assigned to the two CYP2C19*17 genotypes. The aim of this study was to provide a critical summary, helpful to prescribers...
  6. doi request reprint Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example
    Alain Li-Wan-Po
    National Genetics Education and Development Centre, c o Birmingham Women s Hospital, Edgbaston, UK
    Eur J Clin Pharmacol 66:369-74. 2010
    ..To illustrate the interface of pharmacogenetics and therapeutic drug monitoring and to estimate target blood level for imatinib in the treatment of chronic myelogenous leukemia..
  7. ncbi request reprint Personalised medicine: who is an Asian?
    Alain Li Wan Po
    National Genetics Education and Development Centre, Birmingham, UK
    Lancet 369:1770-1. 2007
  8. pmc Dose-response of minor analgesics in acute pain
    Alain Li Wan Po
    National Genetics Education and Development Centre, Birmingham and Centre for Evidence Based Pharmacotherapy, Nottingham, UK
    Br J Clin Pharmacol 63:268-70. 2007
  9. ncbi request reprint How high should total pain-relief score be to obviate the need for analgesic remedication in acute pain? Estimation using signal detection theory and individual-patient meta-analysis
    A Li Wan Po
    Centre for Evidence Based Pharmacotherapy, Nottingham, UK
    J Clin Pharm Ther 31:161-5. 2006
    ..A pain relief score 50% of the maximum is often used as a clinically meaningful outcome in meta-analyses of analgesic trials. This arbitrary value requires validation...